The Europe Immunotherapy Drugs Market was valued at $86100 Million in 2024 and projected to reach to $176700 Million by 2029, representing a compound annual growth rate of 15.5%. Europe's immunotherapy drugs market is poised for sustained expansion through 2029, driven by increasing cancer incidence, aging populations, and growing healthcare expenditure across major economies.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Europe's immunotherapy drugs market is valued at $86.1 billion in 2024, with a robust CAGR of 15.5% projected through 2029, reaching $176.7 billion. This growth trajectory outpaces many global regions, driven by advanced healthcare systems and increasing treatment adoption.
The UK dominates Europe's immunotherapy market at $45.7 billion, followed closely by Germany at $42.3 billion. France ($17.6 billion) and Italy ($13.3 billion) represent significant secondary markets, collectively accounting for substantial market share across the continent.
European markets are experiencing accelerated adoption of checkpoint inhibitors and CAR-T cell therapies. Strong regulatory frameworks from EMA and national health authorities facilitate rapid market entry, while healthcare systems increasingly reimburse advanced immunotherapy treatments.
Europe's mature healthcare infrastructure, high cancer prevalence, and strong R&D capabilities position the region as a critical market for immunotherapy development. Established patient access programs and clinical trial networks support rapid commercialization and market penetration.
| Report Metric | Details |
|---|---|
| Base Year | 2024 |
| Fastest Growing Segment | OTHER IMMUNOTHERAPY DRUGS (Type) |
| Forecast Period | 2024-2029 |
| Growth Rate | CAGR of 15.3% from 2024 to 2029 |
| Largest Segment | HOSPITALS (End User) |
| Market Size Base Year (Billions) | ~USD 284.92 (2024) |
| Revenue Forecast (Billions) | ~USD 580.6 (2029) |
| Segments Covered | Type, Application, Route Of Administration, End User |
4 segment dimensions are covered across the global market.
| Country | 2025 size (native) |
|---|---|
| Germany | USD 42300 Million |
| UK | USD 45700 Million |
| France | USD 17600 Million |
| Italy | USD 13300 Million |
| Spain | USD 9400 Million |
| Rest Of Europe | USD 17700 Million |
Europe's immunotherapy drugs market was valued at $86.1 billion in 2024 and is expected to grow to $176.7 billion by 2029.
Europe's immunotherapy drugs market is projected to grow at a compound annual growth rate (CAGR) of 15.5% from 2024 to 2029.
Major European markets include Germany, France, the United Kingdom, Italy, and Spain, which collectively represent significant demand for immunotherapy treatments.
Key drivers include aging populations, rising cancer incidence, EMA regulatory approvals, favorable reimbursement policies, and expanding treatment indications beyond oncology.
Europe represents a mature, well-regulated market with strong healthcare infrastructure and high adoption rates, positioning it as a critical growth region alongside North America and Asia-Pacific.
This study involved four major activities in estimating the current size of the immunotherapy drugs market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments.
Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the immunotherapy drugs market. The secondary sources referred to for this research study include publications from government sources, such as National Institutes of Health (NIH), United States Food and Drug Administration (US FDA), World Health Organization (WHO), European Pharmaceutical Review, American Society of Gene & Cell Therapy (ASGCT), European Society of Gene and Cell Therapy (ESGCT), European Medicines Agency (EMA), and the Alliance for Regenerative Medicine (ARM). Secondary sources also include corporate and regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines and research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the immunotherapy drugs market, which was validated through primary research. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess the prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information.

To know about the assumptions considered for the study, download the pdf brochure
The global size of the immunotherapy drugs market was estimated through multiple approaches. A detailed market estimation approach was followed to estimate and validate the value of the immunotherapy drugs and other dependent submarkets. The research methodology used to estimate the market size includes the following:

To know about the assumptions considered for the study, Request for Free Sample Report
After arriving at the overall market size—using the market size estimation processes—the market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics of each market segment, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the immunotherapy drugs market.
Immunotherapy drugs are a broad category of therapeutic agents that help stimulate the body's immune system to combat diseases. These drugs include antibody therapies, cell & gene therapy, inhibitor drugs, and other drugs such as oncolytic viral therapy and cancer vaccines. These drugs are engineered to enhance the immune response or counteract the immune system's regulatory mechanisms, thereby enabling the body to effectively target and eliminate disease-causing agents or cells. Immunotherapy drugs are used to treat various medical conditions, including cancer, autoimmune diseases, hematology, osteology, neurology, and other therapy areas (such as ophthalmology, dermatology, and cardiovascular disorders).
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
Full forecast, segment splits, and company analysis for all Immunotherapy Drugs Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report